AstraZeneca’s Post

🙄Oh goody, more consolidation within the manufacturer space that will surely reduce the price of the therapies for endocrine and related diseases 🙄 (are you listening @FTC?) But let's just continue to let the hospitals, pharmacies, PBMs, health plans and the broker/consultants take the heat for the price of brand pharmaceuticals in the United States 🙄 .It is well past time for the pharmaceutical manufacturers to explain why the United States pays 333% more, on a net basis, than all other tier-one countries. Reform is desperately needed in the pharmacy ecosystem, but the manufacturers must acknowledge the major part they play in manipulating the system and start actively participating in solutions. SHARx, LLC Pharmaceutical Care Management Association (PCMA) National Association of Chain Drug Stores (NACDS) CVS Health CVS Caremark Navitus Health Solutions Maxor National Pharmacy Services, LLC MedImpact Healthcare Systems, Inc. Express Scripts by Evernorth Optum Optum Rx Drexi Mark Cuban Cost Plus Drug Company, PBC #SHARx #EnoughisEnough #Risingtides #RisingTidesArmy #joinus

Gilead Sciences, a biopharmaceutical company, agreed to acquire CymaBay Therapeutics, a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases, for $4.3bn. "We are looking forward to advancing seladelpar by leveraging Gilead's long-standing expertise in treating and curing liver diseases. Building on the strong research and development work by the CymaBay team to date, we have the potential to address a significant unmet need for people living with PBC and expand on our existing broad range of transformational therapies," Daniel O'Day, Gilead Sciences Chairman and CEO. CymaBay Therapeutics (led by Sujal Shah) is advised by Centerview Partners, Lazard and LifeSci Advisors, LLC (led by Peter (PJ) Kelleher). Gilead Sciences (led by Daniel O'Day) is advised by Bank of America and Guggenheim Partners. #MergersAcquisitionsDivestitures #Biotechnology #Pharmaceuticals

CymaBay Therapeutics CBAY 0.14%increase; green up pointing triangle  shares jumped nearly 25% and hit a new record high in early trading Monday after the clinical-stage biopharmaceutical company agreed to be acquired by Gilead Sciences GILD -0.69%decrease; red down pointing triangle  for $4.3 billion.Gilead is paying $32.50 a share in cash for CymaBay, a roughly 27% premium to Friday’s closing price of $25.69 and well above CymaBay’s prior all-time high of $26.35 reached during Friday’s session. CymaBay said the FDA set a target action date of Aug. 14 for the application, adding that the agency isn’t currently planning to hold an advisory committee meeting to discuss the application. #CymaBay #gilead https://lnkd.in/gf4668tw

AbbVie, an American pharmaceutical company, completed the acquisition of Landos Biopharma, Inc., a clinical stage biopharmaceutical company, for $212m. "Many people living with IBD are not able to achieve or maintain remission and continue to experience debilitating symptoms. The addition of NX-13 complements our portfolio in immunology and strengthens our collective efforts to transform standard of care. I want to commend the Landos team for their efforts in advancing our shared mission of developing medicines for those who need it most," Kori Wallace, AbbVie Vice President, Global Head of Immunology Clinical Development. Landos (led by Gregory Oakes and Tiago Girao) was advised by Jefferies and Cooley LLP (led by Kevin Cooper). Jefferies was advised by Freshfields Bruckhaus Deringer (led by Damien Zoubek). AbbVie (led by Richard A. Gonzalez and Roopal Thakkar) was advised by Paul, Weiss, Rifkind, Wharton & Garrison LLP (led by Krishna Veeraraghavan and Benjamin Goodchild). #MergersAcquisitionsDivestitures #Pharmaceutical #Biotechnologies #Clinical

💥AbbVie acquired Landos Biopharma in a deal announced on March 25, 2024. The acquisition bolsters AbbVie's presence in the autoimmune and inflammatory diseases space. 🌞Focus: Landos is a clinical-stage biopharmaceutical company developing novel oral therapies for autoimmune diseases. 🌞Key Asset: AbbVie gains access to Landos' lead drug candidate, NX-13, a first-in-class treatment for ulcerative colitis. 🌞Deal Value: AbbVie agreed to pay $20.42 per share for Landos, amounting to roughly $137.5 million upfront. Additionally, there's a potential milestone-based payment of up to $75 million. Overall, this acquisition strengthens AbbVie's portfolio in a key therapeutic area and brings a promising drug candidate for ulcerative colitis under their wing. #AbbVie #Landos #Acquisition #BioPharma #Healthcare #LifeSciences #MedicalTechnology #Pharmaceuticals #inflammatory

#TrendingStockTuesdays 📈 This week's selection for the Tuesday Trend is: Soleno Therapeutics, Inc.(SLNO), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. ▪️Closing Price: $49.50 ▪️Trading Volume: 480.800 shares traded ▪️Stop Loss: 29% ▪️Trend Strength: 1 ▪️20 Day Trend Line: 33.24% ▪️100 Day Trend Line: 1,137% This stock was identified with Trending Stocks by Stock Trend Spotter, LLC. Free trial: https://trendingstocks.io (This is not a recommendation to purchase.) #stockmarketnews #stockmarket #investing #investors #clinicaltrials #biopharmaceuticals

#AbeonaTherapeutics Inc shares jumped 15% to $4.96 in late-morning trading on Monday after the US Food and Drug Administration (FDA) said it would expedite a review of pz-cel (prademagene zamikeracel), the company's proposed treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare, inherited connective-tissue disorder.   The clinical-stage biopharmaceutical company had previously stated that it expected an FDA decision on priority-review status by late November.  Abeona noted the FDA set a target action date of May 25 for the application, and that the agency doesn't currently plan to hold an advisory committee meeting.  The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.  Shares of Abeona Therapeutics have gained 73% year to date.  More at #Proactive #ProactiveInvestors http://ow.ly/yxfR1053QxR

Will the JPM Healthcare Conference set the stage for unprecedented biopharma M&A in 2024? With more than 10 biopharma M&A deals over $1 billion in 2023, the bar is high and investors eagerly expect at least 1 splashy deal. Below the largest 10 biopharma M&A deals of 2023: 1) Bristol Myers $BMY / Karuna $KRTX $14 billion 2) Merck $MRK / Prometheus $RXDX $10.8 billion 3) AbbVie $ABBV / ImmunoGen $IMGN $10.1 billion 4) AbbVie $ABBV / Cerevel $CERE $8.7 billion 5) Astellas / Iveric Bio $ISEE $5.9 billion 6) Eli Lilly $LLY / Dice Therapeutics $DICE $2.4 billion 7) GSK $GSK / Bellus Health $BLU $2 billion 8) AstraZeneca $AZN / CinCor $CINC $1.8 billion 9) Eli Lilly $LLY / Point Biopharma $PNT $1.4 billion 10) Ironwood $IRWD / VectivBio $VECT $1 billion https://lnkd.in/eHT_9CCR

Idiopathic pulmonary fibrosis is a progressive and life-limiting #lungdisease. Explore the evolving IPF treatment landscape and learn how early-stage biopharmaceutical teams can meet emerging development challenges and chart a new roadmap to success in our whitepaper. https://ow.ly/FPym50QIEB6 #ShareYourColours #RareDiseaseDay

Idiopathic pulmonary fibrosis (#IPF) is a progressive and life-limiting #lungdisease. Explore the evolving IPF treatment landscape and learn how early-stage biopharmaceutical teams can meet emerging development challenges and chart a new roadmap to success in our whitepaper. https://ow.ly/hRqm50Q4qzI #WorldCOPDDay #COPD #BreathingisLife-ActEarlier